Our latest Drug Safety Newsletter offers healthcare professionals essential information on the safe and effective use of medicines. It includes information on:
➡️ Fezolinetant: Risk of drug induced liver injury with new recommendations on liver function monitoring.
➡️ Enzalutamide and digoxin: Laboratory test interference may cause falsely elevated digoxin plasma levels, with a reminder of the existing interaction.
➡️ Glucagon-like peptide-1 (GLP-1) analogues: Highlight and reminder of certain safety aspects.
➡️ Updates to product information: Macrogol 3350 with electrolytes (oral use), trimethoprim, and domperidone medicines.
To download the newsletter, visit our website: hpra.ie/safety-informa…
➡️ Fezolinetant: Risk of drug induced liver injury with new recommendations on liver function monitoring.
➡️ Enzalutamide and digoxin: Laboratory test interference may cause falsely elevated digoxin plasma levels, with a reminder of the existing interaction.
➡️ Glucagon-like peptide-1 (GLP-1) analogues: Highlight and reminder of certain safety aspects.
➡️ Updates to product information: Macrogol 3350 with electrolytes (oral use), trimethoprim, and domperidone medicines.
To download the newsletter, visit our website: hpra.ie/safety-informa…